Another early-phase clinical trial at MD Anderson is exploring the safety and efficacy of the intraperitoneal administration of atezolizumab (PD-L1 inhibitor) and bevacizumab (VEGF inhibitor) in advanced recurrent peritoneal mesothelioma refractory to multiple prior lines of therapy. This evidence concerns the gene CD274 and peritoneal mesothelioma.